Celularity - Class A (CELU) closed at $0.94 on October 28, 2026, up 19.0% from the previous close, on volume of 336,558 shares (30-day average 149,635).
Data as of October 28, 2026.
Celularity Partners with Vesalius on U.S. Peptide Manufacturing
TipRanks (Thu, 29-Oct 9:47 AM ET)
Business Wire (Thu, 29-Oct 9:00 AM ET)
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Globe Newswire (Thu, 22-Oct 8:00 AM ET)
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Globe Newswire (Wed, 30-Sep 11:57 AM ET)
Celularity Announces Naveen Jain to Join Board of Directors
Globe Newswire (Tue, 29-Sep 8:30 AM ET)
Globe Newswire (Thu, 24-Sep 9:15 AM ET)
Business Wire (Thu, 27-Aug 9:00 AM ET)
Celularity Provides Update Regarding Nasdaq Listing Compliance
Globe Newswire (Tue, 25-Aug 7:59 PM ET)
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Celularity - Class A trades on the NASDAQ stock market under the symbol CELU.
As of October 29, 2026, CELU stock price declined to $0.93 with 230,186 million shares trading.
CELU has a beta of 1.94, meaning it tends to be more sensitive to market movements. CELU has a correlation of 0.05 to the broad based SPY ETF.
CELU has a market cap of $30.18 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CELU traded as high as $7.97 and as low as $.56.
The top ETF exchange traded funds that CELU belongs to (by Net Assets): VTI, VXF.
CELU has underperformed the market in the last year with a price return of -53.5% while the SPY ETF gained +13.1%. However, in the short term, CELU had mixed performance relative to the market. It has outperformed in the last 3 months, returning +22.4% vs +4.1% return in SPY. But in the last 2 weeks, CELU shares have been beat by the market, returning -29.0% compared to an SPY return of 0.0%.
CELU support price is $.86 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELU shares will trade within this expected range on the day.